LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

43.05 -3.63

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

42.5

Max

43.29

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+25.67% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	71M 3.3B
Eelmine avamishind	46.68
Eelmine sulgemishind	43.05

Uudiste sentiment

By Acuity

35%

65%

88 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. veebr 2026, 23:53 UTC

Kuumad aktsiad

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27. veebr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27. veebr 2026, 17:55 UTC

Kuumad aktsiad

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27. veebr 2026, 23:46 UTC

Omandamised, ülevõtmised, äriostud

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27. veebr 2026, 23:33 UTC

Omandamised, ülevõtmised, äriostud

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27. veebr 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

27. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27. veebr 2026, 21:30 UTC

Tulu

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27. veebr 2026, 21:30 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27. veebr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27. veebr 2026, 21:17 UTC

Tulu

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27. veebr 2026, 21:10 UTC

Omandamised, ülevõtmised, äriostud

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27. veebr 2026, 21:09 UTC

Omandamised, ülevõtmised, äriostud

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27. veebr 2026, 21:00 UTC

Tulu

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27. veebr 2026, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27. veebr 2026, 20:24 UTC

Market Talk

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27. veebr 2026, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27. veebr 2026, 20:12 UTC

Market Talk

Nike Seen With Further Challenges in China -- Market Talk

27. veebr 2026, 19:44 UTC

Market Talk

Gold Caps Historic Month -- Market Talk

27. veebr 2026, 19:39 UTC

Tulu

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27. veebr 2026, 19:38 UTC

Tulu

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27. veebr 2026, 18:53 UTC

Omandamised, ülevõtmised, äriostud

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27. veebr 2026, 18:45 UTC

Tulu

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27. veebr 2026, 18:45 UTC

Market Talk

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27. veebr 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

27. veebr 2026, 17:07 UTC

Tulu

Pemex Cuts 4Q Loss As Operating Results Improve

27. veebr 2026, 17:00 UTC

Market Talk

Corn Rides Oil Momentum Higher -- Market Talk

27. veebr 2026, 16:31 UTC

Market Talk

Canadian Economy Shows Resilience -- Market Talk

27. veebr 2026, 16:17 UTC

Market Talk

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27. veebr 2026, 15:49 UTC

Tulu

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

25.67% tõus

12 kuu keskmine prognoos

Keskmine 56.45 USD 25.67%

Kõrge 66 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

88 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.